Article Sidebar
Main Article Content
Identification of Potential Functional Modules and Diagnostic Genes for Crohn’s Disease Based on Weighted Gene Co-expression Network Analysis and LASSO Algorithm
Main Article Content
Abstract
Background/Aims: Accurate diagnosis of Crohn’s disease (CD) is paramount due to its resemblance to other inflammatory bowel diseases. Early and precise diagnosis plays a pivotal role in tailoring personalized treatments, thereby enhancing the quality of life for CD patients.
Materials and Methods: Differential gene expression analysis was conducted to identify genes from the mRNA expression profiles of CD samples, followed by pathway enrichment analysis. The immune cell infiltration levels of each CD patient sample were assessed. Using weighted gene co-expression network analysis, key gene modules linked to CD were found. Hub gene identification was made easier by the construction of protein–protein interaction networks. Next, utilizing the Least Absolute Shrinkage and Selection Operator on the hub genes in the training set, a diagnostic model was created. The accuracy of the model was then confirmed using a different validation set.
Results: Our analysis revealed 651 differentially expressed genes, enriched in leukocyte chemotaxis and inflammation-related pathways. Immunization results showed a higher abundance of T cells CD4 memory resting, macrophages M2, and plasma cells in CD patients. Weighted gene co-expression network analysis linked the turquoise module with macrophages M2. Eight hub genes (APOA1, APOA4, CYP2C8, CYP2C9, CYP2J2, EPHX2, HSD3B1, and LPL) formed the diagnostic model, exhibiting excellent diagnostic performance with area under curve values of 0.94 (training set) and 0.941 (validation set).
Conclusion: The CD diagnostic model, based on hub genes, shows exceptional diagnostic accuracy, providing a valuable reference for CD diagnosis.
Cite this article as: Wang R, Zhao H. Identification of potential functional modules and diagnostic genes for Crohn’s disease based on weighted gene co-expression network analysis and LASSO algorithm. Turk J Gastroenterol. 2025;36(4):209-218.
Article Details
References
1. Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019;12(2):113-122. [CrossRef]
2. Veauthier B, Hornecker JR. Crohn’s disease: diagnosis and management. Am Fam Phys. 2018;98(11):661-669.
3. Saez A, Herrero-Fernandez B, Gomez-Bris R, et al. Pathophysiology of inflammatory bowel disease: innate immune system. Int J Mol Sci. 2023;24(2). [CrossRef]
4. Panés J, Bouzas R, Chaparro M, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Aliment Pharmacol Ther. 2011;34(2):125-145. [CrossRef]
5. Kedia S, Das P, Madhusudhan KS, et al. Differentiating Crohn’s disease from intestinal tuberculosis. World J Gastroenterol. 2019;25(4):418-432. [CrossRef]
6. Horn MP, Peter AM, Righini Grunder F, et al. PR3-ANCA and panel diagnostics in pediatric inflammatory bowel disease to distinguish ulcerative colitis from Crohn’s disease. PLOS ONE. 2018;13(12):e0208974. [CrossRef]
7. Jung Y, Hwangbo Y, Yoon SM, et al. Predictive factors for differentiating between Crohn’s disease and intestinal tuberculosis in Koreans. Am J Gastroenterol. 2016;111(8):1156-1164. [CrossRef]
8. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559. [CrossRef]
9. Ai X, Shen H, Wang Y, et al. Developing a diagnostic model to predict the risk of asthma based on ten macrophage-related gene signatures. BioMed Res Int. 2022;2022:3439010. [CrossRef]
10. Hsueh HW, Weng WC, Fan PC, et al. The diversity of hereditary neuromuscular diseases: experiences from molecular diagnosis. J Formos Med Assoc. 2022;121(12):2574-2583. [CrossRef]
11. Cao X, Duan L, Hou H, et al. IGF-1C hydrogel improves the therapeutic effects of MSCs on colitis in mice through PGE(2)-mediated M2 macrophage polarization. Theranostics. 2020;10(17):7697-7709. [CrossRef]
12. Ngollo M, Perez K, Hammoudi N, et al. Identification of gene expression profiles associated with an increased risk of post-operative recurrence in Crohn’s disease. J Crohns Colitis. 2022;16(8):1269-1280. [CrossRef]
13. Zimmerman NP, Vongsa RA, Wendt MK, et al. Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(7):1000-1011. [CrossRef]
14. Petagna L, Antonelli A, Ganini C, et al. Pathophysiology of Crohn’s disease inflammation and recurrence. Biol Direct. 2020;15(1):23. [CrossRef]
15. Louis TJ, Qasem A, Naser SA. Attenuation of excess TNF-alpha release in Crohn’s disease by silencing of iRHOMs 1/2 and the restoration of TGF-beta mediated immunosuppression through modulation of TACE trafficking. Front Immunol. 2022;13:887830. [CrossRef]
16. Poggioli G, Laureti S, Campieri M, et al. Infliximab in the treatment of Crohn’s disease. Ther Clin Risk Manag. 2007;3(2):301-308. [CrossRef]
17. Aardoom MA, Veereman G, de Ridder L. A review on the use of anti-TNF in children and adolescents with inflammatory bowel disease. Int J Mol Sci. 2019;20(10). [CrossRef]
18. Boronat-Toscano A, Monfort-Ferré D, Menacho M, et al. Anti-TNF therapies suppress adipose tissue inflammation in Crohn’s disease. Int J Mol Sci. 2022;23(19). [CrossRef]
19. Słowińska-Solnica K, Pawlica-Gosiewska D, Gawlik K, et al. Serum inflammatory markers in the diagnosis and assessment of Crohn’s disease activity. Arch Med Sci. 2021;17(1):252-257. [CrossRef]
20. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52(1):65-70. [CrossRef]
21. Ashton JJ, Boukas K, Davies J, et al. Ileal transcriptomic analysis in paediatric Crohn’s disease reveals IL17− and NOD-signalling expression signatures in treatment-naive patients and identifies epithelial cells driving differentially expressed genes. J Crohns Colitis. 2021;15(5):774-786. [CrossRef]
22. Qu J, Fourman S, Fitzgerald M, et al. Low-density lipoprotein receptor-related protein 1 (LRP1) is a novel receptor for apolipoprotein A4 (APOA4) in adipose tissue. Sci Rep. 2021;11(1):13289. [CrossRef]
23. García-Martín E, Martínez C, Ladero JM, Agúndez JA. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther. 2006;10(1):29-40. [CrossRef]
24. Läpple F, von Richter O, Fromm MF, et al. Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003;13(9):565-575. [CrossRef]
25. Zeldin DC, Foley J, Goldsworthy SM, et al. CYP2J subfamily cytochrome P450s in the gastrointestinal tract: expression, localization, and potential functional significance. Mol Pharmacol. 1997;51(6):931-943. [CrossRef]
26. Bystrom J, Thomson SJ, Johansson J, et al. Inducible CYP2J2 and its product 11,12-EET promotes bacterial phagocytosis: a role for CYP2J2 deficiency in the pathogenesis of Crohn’s disease? PLOS ONE. 2013;8(9):e75107. [CrossRef]
27. Reisdorf WC, Xie Q, Zeng X, et al. Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease. PLOS ONE. 2019;14(4):e0215033. [CrossRef]
28. Hettel D, Sharifi N. HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer. Nat Rev Urol. 2018;15(3):191-196. [CrossRef]
29. He M, Li C, Tang W, et al. Machine learning gene expression predicting model for ustekinumab response in patients with Crohn’s disease. Immun Inflamm Dis. 2021;9(4):1529-1540. [CrossRef]
30. Bo L, Fu H, Yang J. Comprehensive analysis of gene expression profiles provides insight into the pathogenesis of Crohn’s disease. Mol Med Rep. 2018;18(3):2643-2650. [CrossRef]